ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Allarity Therapeutics Inc

Allarity Therapeutics Inc (ALLR)

1.78
0.07
( 4.09% )
업데이트: 00:07:16

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
1.78
매수가
1.76
매도가
1.78
거래량
54,511
1.69 일간 변동폭 1.80
1.63 52주 범위 666.00
market_cap
전일 종가
1.71
개장가
1.70
최근 거래 시간
200
@
1.78
마지막 거래 시간
00:10:47
재정 규모
US$ 94,962
VWAP
1.7421
평균 볼륨(3m)
4,635,009
발행 주식
1,412,650
배당수익률
-
주가수익률
-0.12
주당순이익(EPS)
-14.45
매출
-
순이익
-20.42M

Allarity Therapeutics Inc 정보

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Allarity Therapeutics Inc is a clinical-stage, precision medicine company.

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Allarity Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ALLR. The last closing price for Allarity Therapeutics was US$1.71. Over the last year, Allarity Therapeutics shares have traded in a share price range of US$ 1.63 to US$ 666.00.

Allarity Therapeutics currently has 1,412,650 shares in issue. The market capitalisation of Allarity Therapeutics is US$2.42 million. Allarity Therapeutics has a price to earnings ratio (PE ratio) of -0.12.

ALLR 최신 뉴스

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose...

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:...

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc...

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.46-20.53571428572.242.241.632198151.85816501CS
4-3.38-65.5038759695.165.1961.6313751203.11020853CS
12-4.106-69.75874957535.8867.4521.6346350095.12824965CS
26-160.22-98.90123456791621741.63509324319.43690495CS
52-426.56-99.5844422655428.346661.63296062561.89543003CS
156250335.569414-100.000711051-250333.78941492640-167332.37365219583961433.90839923CS
260250335.569414-100.000711051-250333.78941492640-167332.37365219583961433.90839923CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PEVPhoenix Motor Inc
US$ 0.8698
(150.30%)
77.36M
BENFBeneficient
US$ 1.77
(48.74%)
89.79M
FORDForward Industries Inc
US$ 4.98
(42.29%)
15.47M
SNALSnail Inc
US$ 1.015
(39.63%)
3.32M
SOBRSOBR Safe Inc
US$ 5.98
(35.91%)
92.48k
ADDColor Star Technology Company Ltd
US$ 0.3211
(-28.64%)
5.15M
CETXCemtrex Inc
US$ 1.83
(-28.52%)
1.91M
LASELaser Photonics Corporation
US$ 6.92
(-24.62%)
752.15k
ELABElevai Labs Inc
US$ 0.1028
(-22.12%)
17.48M
LSBLakeShore Biopharma Company Ltd
US$ 5.45
(-20.09%)
30.84k
NCNCnoco noco Inc
US$ 0.1764
(33.03%)
118.96M
NVDANVIDIA Corporation
US$ 123.99
(0.93%)
102.5M
BENFBeneficient
US$ 1.77
(48.74%)
89.79M
SQQQProShares UltraPro Short QQQ
US$ 7.525
(-2.40%)
88.68M
PEVPhoenix Motor Inc
US$ 0.8698
(150.30%)
77.36M

ALLR Discussion

게시물 보기
Monksdream Monksdream 2 주 전
ALLR new 52 week low
👍️0
tw0122 tw0122 2 주 전
4.6 + 36% 2 patients staying alive .. Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that two patients enrolled in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy.

The patients had been pre-screened using Allarity’s Drug Response Predictor (DRP®) companion diagnostic, which identified them as having a high likelihood of benefiting from stenoparib, the Company’s novel dual PARP/Tankyrase inhibitor.

This remarkably lengthy treatment period highlights the potential of stenoparib to provide durable clinical benefit, even in heavily pre-treated ovarian cancer patients who have limited treatment options. The trial continues to evaluate stenoparib’s safety and efficacy, showing a confirmed, complete response as well as long term disease stability for multiple patients.

Thomas Jensen, CEO of Allarity Therapeutics, commented on this clinical achievement:

“We are incredibly encouraged by the sustained clinical benefit seen in these patients, who have now been on stenoparib for over a year. For heavily pre-treated ovarian cancer patients, extending life by 52 weeks is particularly noteworthy. Stenoparib’s unique mechanism of action, as both a PARP and Tankyrase inhibitor, sets it apart from other treatments. These results reinforce our belief in stenoparib’s potential as an important new therapy for ovarian cancer patients who have exhausted other treatment options.”

Dr. Fernanda B. Musa, Director of Clinical Research in Gynecology Oncology and site Principal Investigator at the Swedish Cancer Institute for the trial added:

“We have been surprised and excited to see a long duration of response to a single-agent oral therapy in patients with ovarian cancer who had failed multiple other types of treatment. I credit the success to personalized medicine: the pairing of the therapy to the patient’s specific tumor profile. I look forward to seeing further development of this program!”

Allarity is actively planning the further advancement of its stenoparib program, with a focus on accelerating its path toward regulatory approval. The Company remains dedicated to exploring stenoparib’s long-term clinical benefit in DRP®-selected patients and is preparing for the next phase of development. Additional updates on the program’s progress and future trials will be shared in the coming months.

Background Information about the Trial
The above-mentioned trial is a Phase 2, prospective open-label, single-arm study with multiple sites in both the US and the UK. Investigators prescreened women with advanced, recurrent ovarian cancer using Allarity’s DRP® companion diagnostic (CDx), which comprises a complex transcriptomic signature of 414 mRNA biomarkers indicative of drug response or resistance. Each participant was assigned a DRP score, and those with scores above 50 -suggesting a higher likelihood of benefiting from treatment – were selected to receive stenoparib. The selected patients were administered stenoparib under a revised protocol implemented in Q1 2023, which involved a twice-daily dosing regimen (200 mg in the morning and 400 mg in the evening) instead of the previous once-daily 600 mg dose. This change was made to optimize daily drug exposure and target inhibition.

The patients enrolled have advanced through multiple lines of therapy, including platinum, taxanes, anti-angiogenesis inhibitors, and even the recently approved Antibody Drug Conjugate, Elahere. Importantly, most of the enrolled patients to date have been previously treated with a PARP inhibitor. These patients have few, if any, effective treatment options and typically advance through available therapies after only a few months.

About stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/ß-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.

About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients dozens of clinical studies (both retrospective and prospective). The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in the peer-reviewed literature.

👍️0
BLACKBIRDSR-71 BLACKBIRDSR-71 3 주 전
THE PUECE OF SHIT CEO WILL REVERSE AGAIN NEXY WEEK, HE FUCKED INVESTORS ALL HIS CAREER
👍️0
BLACKBIRDSR-71 BLACKBIRDSR-71 3 주 전
REVERSE THIS SCAM HOAX PIECE OF SHIT AND FILL YOUR POCKETS CEO BASTARD
👍️0
BLACKBIRDSR-71 BLACKBIRDSR-71 3 주 전
THE PIECE OF SHIT CEO FUCKED EVERYONE UP THE ASS ONCE AGAIN JUST LIKE THAT PUECE OF SHIT FITZGERALD RNAZ
👍️0
Tom turtles Tom turtles 3 주 전
Buy a Cuspid # for $100 and come up with some bogus product like microwave hot water tanks or solar panels ...that are actually a couple mirrors in your basement...
👍️0
Tom turtles Tom turtles 3 주 전
Hahahaha.....
What a piece of crap
👍️0
tw0122 tw0122 1 월 전
In consideration of this extension, and the Company not achieving the minimum patient enrollment, by July 1, 2022, as set out in the second amendment to the Eisai License Agreement, the Company agreed to pay a one-time payment to Eisai of $1,250,000 (the “Extension Payment”) as follows: (i) $400,000, (ii) $425,000 within 10 days from August 19, 2024 and (iii) $425,000 upon completion of a 10 million dollar capital raising, but in no event later than September 1, 2024. To date, the Company has paid the full Extension Payment to Eisai, and no payments are currently outstanding.
👍️0
tw0122 tw0122 1 월 전
The Preferred Stock is convertible, at the option of the holders and, in certain circumstances, by the Company, into the Common Stock, as determined by dividing the net purchase price of $90 per share by the conversion price of $0.17, at the option of the holders. The conversion price can be adjusted pursuant to the Certificates of Designation for stock dividends and stock splits, subsequent rights offering, pro rata distributions of dividends or the occurrence of a fundamental transaction. The holders of the Preferred Stock have the right to require the Company to redeem their shares of preferred stock for cash at 100% of the stated value of such shares commencing after the earlier of the receipt of stockholder approval of the Amendment and 60 days after the Closing Date and until 90 days after the Closing Date. The Company has the option to redeem the Preferred Stock for cash at 100% of the stated value commencing after the 90th day following the Closing Date, subject to the holders’ rights to convert the shares prior to such redemption.
👍️0
Acehole Acehole 2 월 전
New round of bagholders getting sucked in.
👍️0
trendzone trendzone 2 월 전
Can't argue with that not being the case, it's an outright major crime that the SEC lets these criminals in their cheap suits getaway with it,day in and day out, sure many start out believing they can become something that could turn into something good,but most turn into a toxic cesspools with no way out,other than becoming the self-centered selfish toxic slobs they become, and think they are doing nothing wrong ripping off the public and lining their pockets and over compensating themselves with greedy payouts,that none of them deserve,when the company's are using burning through cash to support their scam until the worthless brainless SEC some times do their usual half-ass job of shutting them down,after the retail public ends up losing many millions,to be one of them I guess you have to have a few bucks buyout a shell company and hype of some kind of BS that you have something great,and sucker in the public to believe the BS, and have a few cheap suits,for when you get involved with the toxic note dilution lenders,and the pump and dump promoters.
👍️0
Acehole Acehole 2 월 전
There is a reason many institutional investors won't invest in sub $5 stocks. They are generally all bottom feeding pump and dump scams. Dilution followed by reverse split followed by more dilution etc etc until Nasdaq finally boots them off the exchange. Jackass CEO and management give themselves bonuses just prior to bankruptcy and ride off into the sunset with all the money stole and have zero liability for the fraud they committed. Man, what a racket. How do I get in on it?
👍️0
trendzone trendzone 2 월 전
Funny how they are trying to scare share holders into voting yes for a RS, mean while they screwed over any one who got stuck in the last one they just did in May, $5.00 to $0.15 in just three months,great investment only if you were short, or a naked shorting hedge fund criminal enterprise, wouldn't be surprised if they themselves shorted their own stock back then, sure they want a RS so they can keep the toxic slob formula in place,and keep their over paid salaries from getting hit and cut in half,and keep sucking money out of it on the backs of the public.
👍️0
Law of Averages Law of Averages 2 월 전
I wonder if this will hit $1.00 it's moving pretty fast
👍️0
Awl416 Awl416 2 월 전
8k was released
👍️0
Law of Averages Law of Averages 2 월 전
Looks like a short squeeze has started after hours .27 and climbing
👍️0
georgie18 georgie18 2 월 전
ALLR...18... https://schrts.co/AshjZBCw...Could get squeezed here with some tight bands...🥳
👍️0
Law of Averages Law of Averages 2 월 전
BB bands are super tight on ALLR this could see a hard bounce up.
👍️0
TheOTCstocksGuy TheOTCstocksGuy 2 월 전
Absolute trash!! Been saying it for months but no one listens as usual!!
👍️0
gdog gdog 2 월 전
pretty much
👍️0
 just Scottie just Scottie 2 월 전
In the toilet now
👍️0
gdog gdog 2 월 전
ALLR recieves a well notice trade accordingly
👍️0
 just Scottie just Scottie 2 월 전
I haven’t been a shareholder long enough I guess. I didn’t get an email.
I guess to vote on the RS, stock options lol and new officers
👍️0
gdog gdog 3 월 전
gosh i don't know I usually just delete without looking much what does it look like?
👍️0
 just Scottie just Scottie 3 월 전
Did u get an email to vote for the split?
👍️0
gdog gdog 3 월 전
agree
👍️0
 just Scottie just Scottie 3 월 전
Getting an extension and postpone the split and get some good news is the only way we stave off the wolves
👍️0
 just Scottie just Scottie 3 월 전
Someone just said short shares are over $3 million
👍️0
gdog gdog 3 월 전
yup lets see how far they take it down am also done buying.
👍️0
 just Scottie just Scottie 3 월 전
I’m afraid to ave down again
Every time I have it plunges more
👍️0
 just Scottie just Scottie 3 월 전
Yes big time
👍️0
gdog gdog 3 월 전
lol i was typing as you were posting yes we need g/news
👍️0
gdog gdog 3 월 전
yes I'm down a good bit also we need good news and hurry
👍️0
 just Scottie just Scottie 3 월 전
Company needs to majorly combat this with some good news
👍️0
gdog gdog 3 월 전
that was ending 6-30
👍️0
gdog gdog 3 월 전
https://www.marketbeat.com/stocks/NASDAQ/ALLR/short-interest/
700,000 sold short in the last 2 wks
👍️0
 just Scottie just Scottie 3 월 전
They are doing a good job. Lost my ass
Doesn’t help if the company may be selling too
👍️0
gdog gdog 3 월 전
I added a few today gulp all markets down today. the shorts are trying to destroy it
👍️0
 just Scottie just Scottie 3 월 전
Selling is relentless brother. Where the hell does it all come from
👍️0
 just Scottie just Scottie 3 월 전
That will be great
👍️0
gdog gdog 3 월 전
understood still think buyout
👍️0
 just Scottie just Scottie 3 월 전
Well unfortunately they need to maintain a dollar to stay on the daq
👍️0
gdog gdog 3 월 전
17.5 m outstanding don't let people worry you about an RS
👍️0
 just Scottie just Scottie 3 월 전
Gonna be tough sledding here. So much downward pressure due to the RS threat
Shorts and pump and dumpers have the upper hand
👍️0
gdog gdog 3 월 전
few hundred isn't wwhat I'm looking for I wants k's
look https://investorshub.advfn.com/Bottom-Swing-Plays-29717
👍️0
 just Scottie just Scottie 3 월 전
Everyone dumped from 18 cents
Hoping news of new trial comes today
👍️0
gdog gdog 3 월 전
BUY out coming ??????????
👍️0
Law of Averages Law of Averages 3 월 전
Agreed. ALLR moving up hella quick.
👍️0
 just Scottie just Scottie 3 월 전
Shorty could shit themselves here soon.
👍️ 1
Zardiw Zardiw 3 월 전
Stop sugar coating it.......say it like it is...........

Z
👍️0

최근 히스토리

Delayed Upgrade Clock